Skip to main content
Premium Trial:

Request an Annual Quote

Astellas to Use Tokyo Tech's Supercomputer to Develop Dengue Antivirals

Premium

Astellas Pharma said this week that it has signed an agreement with the Tokyo Institute of Technology that will allow it to use Tokyo Tech's TSUBAME2.0 petaflop-class supercomputer to discover candidates for treating neglected tropical diseases caused by dengue virus.

Astellas said that the partnership will involve two phases. In the first, the researches will mine public information such as patents and published articles to obtain useful knowledge about treatments for diseases caused by dengue virus. In the second phase, they will use in silico screening to identify compounds that are predicted to have anti-dengue virus capabilities.

According to Astellas, Tokyo Tech will be responsible for the data mining and in silico screening calculations of commercially available compounds while Astellas will be in charge of preparing input data for mining, selecting, and listing of hit compounds that will be evaluated.

This is the second research partnership between Astellas and Tokyo Tech. Last summer, they worked on discovering potential candidates for treating NTDs caused by protozoan parasites

Filed under

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.